Novo Nordisk A/S (NYSE:NVO) Shares Sold by Atwater Malick LLC

Atwater Malick LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 2.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 162,228 shares of the company’s stock after selling 4,604 shares during the quarter. Novo Nordisk A/S comprises 4.7% of Atwater Malick LLC’s holdings, making the stock its 7th biggest position. Atwater Malick LLC’s holdings in Novo Nordisk A/S were worth $13,955,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVO. International Assets Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC lifted its position in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Marshall Wace LLP increased its position in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after purchasing an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $42,017,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 5.2 %

Novo Nordisk A/S stock opened at $78.74 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company’s fifty day simple moving average is $98.33 and its 200-day simple moving average is $117.69. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.